Affini-T Therapeutics Nachrichten und Aktivitäten
Führungskräfte
Siehe das Organigramm mit seine 9 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Affini-T Therapeutics
- Jak Knowles, Co-Founder, President, Chief Executive Officer and Di...
- Helen Kim, Director
- Jill Desimone, Director
Letzte Veränderungen der Führungskräfte auf Affini-T Therapeutics
- Loïc Vincent, Chief Scientific Officer, hat das Unternehmen verlassen (Nachrichten veröffentlicht am 2, April 2025).
- Loïc Vincent, Chief Scientific Officer, hat das Unternehmen verlassen (Nachrichten veröffentlicht am 2, April 2025).
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Affini-T Therapeutics nachzuverfolgen.
Biotechnologie
Affini-T Therapeutics hat 2.350 Konkurrenten , einschließlich Eurofins (Luxemburg), Lonza (Schweiz) und Johnson & Johnson Innovative Medicine DIA (USA).
Popular M&A news in Biotechnologie
- Transcarent and Accolade have merged (veröffentlicht am 9, April 2025)..
- Kashiv BioSciences hat gerade eine Spendenaktion von 150 Millionen Dollar angekündigt. (veröffentlicht am 7, April 2025).
- Atsena Therapeutics hat gerade eine Spendenaktion von 150 Millionen Dollar angekündigt. (veröffentlicht am 4, April 2025).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach Affini-T Therapeutics
- Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics to Present Data from Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Affini-T Therapeutics
- Affini-T Therapeutics to Present Preclinical Data from its Programs Targeting KRAS G12D and p53 R175H and Two Trials in Progress at the American Association for Cancer Research (AACR) Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Affini-T Therapeutics
- Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer | Affini-T Therapeutics
- Affini-T Therapeutics to Present Preclinical Gene Editing Data from its Program Targeting KRAS G12D at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting | Affini-T Therapeutics
- Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
- Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations - Affini-T Therapeutics
- View more press releases Close
Social media about Affini-T Therapeutics
- Affini-T Therapeutics auf Wikipedia, Google News & Yahoo Finance
- Affini-T Therapeutics auf LinkedIn, Twitter & YouTube
